TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age\>=18years~2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<=2 and a life expectancy \>= 12 weeks;~3. histological-proven, HER-2 negative measurable stage IV disease;~4. exposure to anthracyclines, taxanes either in the neoadjuvant/adjuvant or in the metastatic setting and had documented disease progression after the firstline or secondline treatment~5. Patients previously treated with radiotherapy were eligible for the study, provided that measurable disease existed outside the radiation field.~6. At least 3 weeks from the prior chemotherapy or radiotherapy. At least 2 weeks from the prior endocrine therapy.~Exclusion Criteria:~1. Patients with active infection or other serious underlying medical conditions~2. Patients had prior treatment with 5-FU infusion and/or oxaliplatin therapy~3. Inadequate bone marrow, liver, renal, medullary, and cardiac functions~4. Evidence of spinal cord compression or brain metastasis~5. History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer~6. Pregnant or lactating women~7. Serious uncontrolled intercurrent infection~8. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding~9. Serious non-bleeding wound, peptic ulcer or bone fracture~10. Prior dihypopyrimidine dehydrogenase deficiency~11. Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanlised antibodies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Avastin + mFOLFOX6 (Type: EXPERIMENTAL): Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Main Inclusion at Screening (Visit 1):~* Men and women 19 years or older with OAB symptoms for ≥ 3 months.~* Subject who is willing and able to complete the micturition diary correctly.~* Subject who is willing and able to provide informed consent indicating that they understand the purpose and procedures required for the study~Exclusion Criteria:~* Clinically significant Stress urinary incontinence or Mixed urinary incontinence where stress is the predominant factor~* Diagnosed with interstitial cystitis or bladder pain syndrome~* Clinically significant pelvic organ prolapse~* Subject who has neurologic status which is able to effect vesical function, such as multiple sclerosis, Spinal Injury or Parkinson's disease~* Medical history of malignant tumor in urinary system or pelvic organs~* Clinically significant bladder outlet obstruction or more than 200mL of post-void residual volume

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): DA-8010 placebo + Solifenacin succinate placebo
- DA-8010 2.5mg (Type: EXPERIMENTAL): DA-8010 2.5mg + Solifenacin succinate placebo
- DA-8010 5mg (Type: EXPERIMENTAL): DA-8010 5mg + Solifenacin succinate placebo
- Solifenacin 5mg (Type: ACTIVE_COMPARATOR): DA-8010 placebo + Solifenacin succinate 5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed SARS-CoV-2 infection within 5 days prior to randomization~* Initial onset of COVID-19 signs/symptoms within 5 days prior to the day of randomization and at least 1 of the specified COVID-19 signs/symptoms present on the day of randomization~* Fertile participants must agree to use a highly effective method of contraception~* Has at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19~Exclusion Criteria:~* History of or need for hospitalization for the medical treatment of COVID-19~* Prior to current disease episode, any confirmed SARS-CoV-2 infection~* Known medical history of active liver disease~* Receiving dialysis or have known moderate to severe renal impairment~* Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment~* Suspected or confirmed concurrent active systemic infection other than COVID-19~* History of hypersensitivity or other contraindication to any of the components of the study intervention~* Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4~* Has received or is expected to receive convalescent COVID-19 plasma~* Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit~* Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 through the long-term follow-up visit~* Known prior participation in this trial or other trial involving PF-07321332~* Oxygen saturation of \<92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition~* Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-07321332/ritonavir (Type: EXPERIMENTAL): Orally administered PF-07321332+ritonavir
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Enthesitis Related Arthritis (ERA) as defined by International League of Associations for Rheumatology (ILAR);~* Disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location;~* Inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate.~Exclusion Criteria:~* Any ILAR Juvenile Idiopathic Arthritis (JIA) subtype other than ERA;~* Psoriasis or a history of psoriasis in the patient or first-degree relative;~* Presence of Immunoglobulin M (IgM) rheumatoid factor;~* Presence of systemic JIA;~* History of inflammatory bowel disease;~* previous biologic therapy including anti-tumor necrosis factor (anti-TNF) therapy with a potential impact on pediatric ERA;~* Infection(s) requiring treatment with IV anti-infectives within 30 days prior to Baseline or oral anti-infectives within 14 days prior to Baseline.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Double-blind Placebo EOW (Type: PLACEBO_COMPARATOR): Placebo for adalimumab every other week (eow) for 12 weeks.
- Double-blind Adalimumab EOW (Type: EXPERIMENTAL): Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
- Open-label Adalimumab EOW (Type: EXPERIMENTAL): Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of HF ≥ 3 months, with either preserved or reduced LVEF~2. Diagnosis of NYHA Class III HF (historical assessment documented at screening visit)~3. Subjects with reduced LVEF must be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB. Beta blockers and ACE-I (or ARB) doses should be stable for one month prior to study entry.~4. At least 1 HF hospitalization within 12 months of Screening Visit~5. Subjects with pulmonary artery branch diameter sized between 7mm and 15mm (implanted vessel)~Exclusion Criteria:~1. Subjects with history of recurrent (\> 1) pulmonary embolism or deep vein thrombosis~2. Subjects, in the Investigator's opinion, unable to tolerate a right heart catheterization~3. Subjects who have had a major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of Screening Visit~4. Subjects with Cardiac Resynchronization Device (CRT) implanted ≤ 3 months prior to enrollment~5. Subjects with a Glomerular Filtration Rate (GFR) \<25 ml/min who are non-responsive to diuretic therapy or who are on chronic renal dialysis~6. Subjects likely to undergo heart transplantation within 6 months of Screening Visit~7. Subjects with congenital heart disease or mechanical right heart valve(s)~8. Subjects with known coagulation disorders~9. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TREATMENT Group (Type: ACTIVE_COMPARATOR): Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
- CONTROL Group (Type: PLACEBO_COMPARATOR): Standard of care HF management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed melanoma of the skin: Breslow, Clark, histological type. Location of the primary, clinical, or pathological regional status.~* Complete staging demonstrating the presence of distant metastases, either visceral or in soft tissues or bone tissue: Brain, Lung, Abdomen, and Pelvis CT and bone scintigraphy.~* Objectively measurable disease by clinical or radiological means~* Karnofsky's Performance Status is more significant than 70%~* Life expectancy greater than three months~* Patients over 18 years old~* Informed consent from the patient to participate in the protocol~Exclusion Criteria:~* Age greater than or equal to 65 years~* Ongoing active infections, including viral immunodeficiency~* Previous chemotherapy within less than two months~* Concomitant malignant tumors (e.g., Chronic Lymphocytic Leukemia, etc.)~* Uncontrolled concomitant diseases (Hypertension, unstable Diabetes mellitus, renal diseases requiring dialysis)~* Situations or conditions requiring urgent surgical intervention, such as intestinal obstruction due to metastasis~* Pregnancy or lactation~* Concurrent participation in other therapeutic research protocols~* Any condition that compromises the objectives of this study.~Removal Criteria from the Study:~* By the patient's decision to discontinue the study.~* Intolerable adverse reactions, according to WHO Criteria Grading Toxicities~* Intercurrent illness that may compromise the patient's life or interfere with the treatment study evaluation~* Requirements for concomitant medication that may interfere with study results.~* Failure to complete the study entirely~* Failure to follow up on the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAPCells (Type: EXPERIMENTAL): Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. KPS≥70~2. Diagnosis of pathologically positive lymph node thoracic esophageal cancer~3. Complete resection~4. Adequate organ function:~Hematopoietic Absolute granulocyte count at least 1,500/mm\^3 Platelet count at least 150,000/mm\^3 Hemoglobin at least 10 g/dL Hepatic Not specified Renal Creatinine no greater than 1.5 mg/dL AND/OR Creatinine clearance at least 65 mL/min Calcium no greater than 11 mg/dL Cardiovascular No uncontrolled heart disease No uncontrolled hypertension~Exclusion Criteria:~1. Uncontrolled diabetes~2. Interval between surgery and adjuvant therapy more than 3 months~3. Sign of recurrence on CT scan or ultrasound or PET-CT No palpable supraclavicular lymph nodes or involvement after cytology needle aspiration No lymph nodes greater than 1 cm on CT scan~4. With Weight loss greater than 10% from baseline~5. With other prior or concurrent malignancy except basal cell skin cancer or carcinoma in situ of the cervix~6. Be pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Social security beneficiaries affiliated to the LA RAZA UMAE HECMN~* Adults over 18 years old~* Male or female subjects~* Diagnosed with scleroderma (2013 ACR-EULAR)~* Score above the 25th percentile in NIH-PROMIS questionnaire~* Positive result (\> 10 ppm) in the hydrogen breath test~* Normal leukocyte and lymphocyte profiles~* Patients who accept to participate in the study by signing the informed consent form~Exclusion Criteria:~* Gastrointestinal diseases already diagnosed and not associated to systemic sclerosis~* Comorbidities associated to visceral diseases (diabetes, amyloidosis or other infiltrative diseases)~* Currently under biological treatment (or history of biological treatment in the last year) with cyclophosphamide and \> 10 mg prednisone or equivalent~* Allergy or contra-indications to metronidazole or to Saccharomyces boulardii,~* Central venous catheter carriers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Saccaromyces boulardii oral tablet (Type: ACTIVE_COMPARATOR): Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
- Metronidazole plus S. boulardii (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
- Metronidazole (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A subject must meet all of the following inclusion criteria to participate in the study:~* enrolled and completed HEPLISAV or Engerix-B treatment in: DV2-HBV-17 or DV2-HBV-18 and had anti-HBsAg ≥ 10 mIU/mL prior to or during DV2-HBV-18~* previously received a complete primary hepatitis B vaccine series in DV2-HBV-17 or prior to enrollment in DV2-HBV-18~* be otherwise clinically stable in the opinion of the investigator~* be able and willing to provide informed consent~Exclusion Criteria:~A subject who meets any ONE of the following exclusion criteria is not permitted to participate in the study:~* previously enrolled in DV2-HBV-18 and never obtained anti-HBsAg ≥ 10 mIU/mL~* received hepatitis B vaccine off-study after enrolling in DV2-HBV-17 or DV2-HBV-18~* has known history of autoimmune disease~* is unwilling or unable to comply with all the requirements of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* instrumental and clinical diagnosis of every malignant neoplasm~* presence of pain with a neuropathic component in the opinion of the physician~* presence of pain \>=4(NRS)~* PS ECOG \<3~* written informed consent~Exclusion Criteria:~* serum creatinine \>2mg/ml or creatinine clearance \<40 ml/min~* mild or severe hepatic insufficiency~* iatrogenic neuropathy caused by chemotherapeutic agents~* previous allergic reactions to oxycodone and pregabalin~* pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
- B (Type: ACTIVE_COMPARATOR): pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wearable Sensor for Responsive DBS for ET

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* Patient is over 21 years of age~* Patient has had a significant disabling, medication-refractory upper extremity tremor with no evidence of non-ET central nervous system disease or injury for at least three (3) months prior to implantation of Activa SC, PC, or RC device.~* Patient receives Vim electrode and Activa SC, PC or RC device implants, and recovers fully after surgery.~* Patient is available for study participation after their clinical programming appointments for six months.~Exclusion Criteria:~* Medication related movement disorders.~* Any suspicion of Parkinsonian tremor, including presence of Parkinsonian features such as bradykinesia, rigidity, or postural instability.~* Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, continuous neurological disease, hematological disease, or frailty that impact tolerability of the surgery as judged by the screening physicians.~* Patient is undergoing a lead revision surgery.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Subjects with Essential Tremor (Type: EXPERIMENTAL): This cohort will receive deep brain stimulation (DBS) therapy responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C ≥ 70 mg/dL~* High cardiovascular risk (diagnosis of HeFH or ASCVD)~* Be on maximally tolerated lipid-modifying therapy~Exclusion Criteria:~* Total fasting triglyceride ≥500 mg/dL~* Renal dysfunction or nephrotic syndrome or history of nephritis~* Body Mass Index (BMI) ≥50kg/m2~* Significant cardiovascular disease or cardiovascular event in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 180 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete